The FDA approved The Medicines Company’s Raplixa (fibrin sealant) as the first spray-dried fibrin sealant cleared in the US to help control bleeding during surgery, the company announced. The biological product is approved for use in adults to help control bleeding from small blood vessels when standard surgical techniques are ineffective or impractical.
The future of MannKind looks bleak in the wake of poor sales of the firm’s much anticipated flagship product.
As drug prices continue to fall under ever-increasing scrutiny, spending on cancer medicines has hit a new milestone: $100 billion in 2014.
Researchers say they’ve developed a new screening method that can detect ovarian cancer in twice as many women as traditional strategies.
Researchers have uncovered a unique connection between diabetes and Alzheimer’s disease, providing further evidence that a disease that robs people of their memories may be affected by elevated blood sugar, according to scientists at Washington University School of Medicine in St. Louis.
Statins, widely used to lower cholesterol levels, may also slow the progression of prostate cancer in patients receiving hormone therapy, a new study suggests.
Stroke is the third leading cause of death in women, but many are unaware of warning signs and symptoms that are unique to females, a new study says.
The World Health Organization on Friday said that it added a number of new treatments for hepatitis C to its essential medicines list, although the agency noted that “high prices currently make them unaffordable and thus inaccessible to most people who need them.” The WHO also included new drugs for a variety of cancers, including breast cancer and leukaemia, and multi-drug resistant tuberculosis on its list.
The Centers for Medicare & Medicaid Services’ Pioneer Accountable Care Organization (ACO) program saved nearly $400 million in two years, qualifying it for an expansion, the Department of Health and Human Services announced this week.
A high-protein diet may backfire for people at risk for heart disease — increasing the likelihood of weight gain and early death, a new study suggests.
The U.S. Food and Drug Administration has granted breakthrough therapy designation to a Roche Holding AG (RO.EB) leukemia drug, speeding the regulatory review process for the therapy.